Theradaptive receives an $8M investment from 3D Systems for 3D printed implants coated with therapy material.

Share this story

The additive manufacturing (AM) industry is seeing an intriguing new trend – legacy original equipment manufacturers (OEMs) are entering the regenerative medicine space, reshaping the concept of manufacturing in the modern era. 3D Systems is one of the most prominent players in this regard, having recently partnered with Theradaptive to advance bone and tissue growth solutions through 3D printing technology. Established in 2016, Theradaptive is a company based in Maryland that has developed a therapeutic delivery platform for innovative treatments in various areas such as orthopedics, spine, and targeted immuno-oncology.

Theradaptive’s platform is capable of transforming recombinant proteins into material-binding variants, which can be used to coat implants, devices, and injectable carriers. This enables precise therapeutic delivery to any part of the body. The company’s approach has already shown promising results in preclinical studies, surpassing standard care in clinical areas that were previously difficult to reach, such as orthopedic repair, soft tissue repair, and vascular treatment.

Theradaptive has received significant investment, with a total funding of over $50 million, including a $26 million Series A round in June. The company has also obtained three medical device designations from the U.S. Food and Drug Administration. Now, with the partnership between 3D Systems and Theradaptive, the goal is to explore the applications of Theradaptive’s protein-engineering technology in conjunction with 3D Systems’ 3D-printed medical devices. By working together, they hope to develop new treatment options that can enhance patient healing outcomes. 3D Systems has also made an $8 million investment in Theradaptive, underscoring its commitment to personalized healthcare solutions.

3D Systems has long been a pioneer in personalized healthcare, with a strong presence in medical devices. Over the years, the company has collaborated with surgeons to plan more than 150,000 patient-specific cases and has manufactured over two million implants and instruments using additive manufacturing techniques. Since expanding into the bioprinting space in 2021, 3D Systems has solidified its position as a leader in the field. This includes collaborations with United Therapeutics to develop bioprinted lung scaffolds, acquisitions of Volumetric and Allevi (later spun out as Systemic Bio), and the recent release of tissue products.

While the partnership with Theradaptive reveals one direction of 3D Systems’ strategy, it is worth noting that the company is also in talks with Stratasys regarding a potential merger. Stratasys, a long-time competitor, recently entered the regenerative medicine space through a partnership with CollPlant to develop an industrial solution for breast implant production. This partnership is interesting because CollPlant previously had a co-development agreement with 3D Systems. If the merger between Stratasys and 3D Systems becomes a reality, it would create a powerful force in the medical field.

Under the leadership of previous CEO Vyomesh Joshi, 3D Systems has strengthened its presence in medical 3D printing, establishing a robust workflow for medical implants. On the other hand, Stratasys’s PolyJet technology is known for its anatomically accurate medical models, which it offers as a service through Ricoh. The collaboration with Theradaptive offers numerous possibilities, as incorporating targeted treatments into 3D printed implants could potentially yield better results compared to traditional devices. The porous structure commonly used in 3D printed implants provides an ideal environment to incorporate Theradaptive’s medicines, taking personalized medicine to another level.

In summary, the involvement of legacy OEMs like 3D Systems in the regenerative medicine space represents a significant development in the additive manufacturing industry. Through their partnership with Theradaptive, they aim to leverage innovative technology and 3D printing capabilities to advance bone and tissue growth solutions. Additionally, the potential merger between 3D Systems and Stratasys could create a formidable presence in the medical field. Overall, these collaborations have the potential to revolutionize personalized medicine and improve patient outcomes.

Original source


Share this story

Leave a Reply

Your email address will not be published. Required fields are marked *